All results - Drugs and Technologies - Prescribing and Technical Information - Safety Alerts - Medicines and Healthcare products Regulatory Agency - MHRA - East Midlands Academic Health Science Network | Evidence search

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Yellow Card reporting added to second clinical software system

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 20 February 2017 - Publisher: Medicines and Healthcare products Regulatory Agency

Healthcare professionals who use Vision can now report suspected adverse reactions to MHRA directly through their clinical software.

Read Summary

- Remove: Prescribing and Technical Information filter
Don't miss the latest drug safety advice!

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 11 December 2014 - Publisher: Medicines and Healthcare products Regulatory Agency

We are changing our arrangements for sending out email alerts about Drug Safety Update.

Read Summary

- Remove: Prescribing and Technical Information filter
Desiccants in blister packs: reminder of risk of ingestion

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 11 December 2014 - Publisher: Medicines and Healthcare products Regulatory Agency

Take care to tell people receiving blister packs containing a desiccant that the desiccant should not be swallowed.

Read Summary

- Remove: Prescribing and Technical Information filter
Letters sent to healthcare professionals in July 2017

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 15 August 2017 - Publisher: Medicines and Healthcare products Regulatory Agency

Letters were sent about ibrutinib, daclizumab, aflibercept, valproate medicines, and arsenic trioxide.

Read Summary

- Remove: Prescribing and Technical Information filter
Medical Device Alerts issued in July 2017

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 15 August 2017 - Publisher: Medicines and Healthcare products Regulatory Agency

An alert was recently issued about Prismaflex haemofiltration machines.

Read Summary

- Remove: Prescribing and Technical Information filter
Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 18 July 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

Possible illicit drug use should be considered when prescribing medicines that have the potential to interact adversely.

Read Summary

- Remove: Prescribing and Technical Information filter
N-acetylcysteine: risk of false-low biochemistry test results due to interference with Siemens assays

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 18 July 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

N-acetylcysteine may interfere with assays from Siemens ADVIA Chemistry and Dimension/Dimension Vista instruments, leading to false-low biochemistry test results.

Read Summary

- Remove: Prescribing and Technical Information filter
Letters sent to healthcare professionals in June 2016

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 18 July 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

In June 2016, a letter was sent to healthcare professionals about Thalidomide Celgene.

Read Summary

- Remove: Prescribing and Technical Information filter
Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 14 June 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

A signal of increased lower limb amputation (primarily of the toe) in people taking canagliflozin compared with placebo in a clinical trial in high cardiovascular risk patients is currently under...

Read Summary

- Remove: Prescribing and Technical Information filter
Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung

Source: GOV UK - Remove: Medicines and Healthcare products Regulatory Agency - MHRA source - 15 June 2016 - Publisher: Medicines and Healthcare products Regulatory Agency

There have been rare reports of Nexplanon implants having reached the lung via the pulmonary artery. An implant that cannot be palpated at its insertion site in the arm should be located as soon as...

Read Summary

- Remove: Prescribing and Technical Information filter

Filter results by

Results for all evidence | Drugs and Technologies | Prescribing and Technical Information | Medicines and Healthcare products Regulatory Agency - MHRA 1 - 10 of 1165 sorted by relevance / date

Yellow Card reporting added to second clinical software system

Don't miss the latest drug safety advice!

Desiccants in blister packs: reminder of risk of ingestion

Letters sent to healthcare professionals in July 2017

Medical Device Alerts issued in July 2017

Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use

N-acetylcysteine: risk of false-low biochemistry test results due to interference with Siemens assays

Letters sent to healthcare professionals in June 2016

Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients

Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung